These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 38492157

  • 1. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.
    Batteson R, Hook E, Wheat H, Hatswell AJ, Vioix H, McLean T, Alexopoulos ST, Baijal S, Paik PK.
    Target Oncol; 2024 Mar; 19(2):191-201. PubMed ID: 38492157
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
    Sakai H, Morise M, Kato T, Matsumoto S, Sakamoto T, Kumagai T, Tokito T, Atagi S, Kozuki T, Tanaka H, Chikamori K, Shinagawa N, Takeoka H, Bruns R, Straub J, Schumacher KM, Paik PK.
    Jpn J Clin Oncol; 2021 Aug 01; 51(8):1261-1268. PubMed ID: 34037224
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
    Reale ML, Passiglia F, Cappuzzo F, Minuti G, Occhipinti M, Bulotta A, Delmonte A, Sini C, Galetta D, Roca E, Pelizzari G, Cortinovis D, Gariazzo E, Pilotto S, Citarella F, Bria E, Muscolino P, Pozzessere D, Carta A, Pignataro D, Calvetti L, Leone F, Banini M, Di Micco C, Baldini E, Favaretto A, Malapelle U, Novello S, Pasello G, Tiseo M.
    ESMO Open; 2024 Sep 01; 9(9):103680. PubMed ID: 39214048
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
    Kato T, Yang JC, Ahn MJ, Sakai H, Morise M, Chen YM, Han JY, Yang JJ, Zhao J, Hsia TC, Berghoff K, Bruns R, Vioix H, Lang S, Johne A, Le X, Paik PK.
    Br J Cancer; 2024 Jun 01; 130(10):1679-1686. PubMed ID: 38575731
    [Abstract] [Full Text] [Related]

  • 7. Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
    Paik PK, Pfeiffer BM, Vioix H, Garcia A, Postma MJ.
    Adv Ther; 2022 Jul 01; 39(7):3159-3179. PubMed ID: 35543963
    [Abstract] [Full Text] [Related]

  • 8. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
    Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, Smit EF, Cortot AB, Raskin J, Viteri S, Wu YL, Yang JCH, Ahn MJ, Ma R, Zhao J, O'Brate A, Berghoff K, Bruns R, Otto G, Johne A, Felip E, Thomas M.
    JAMA Oncol; 2023 Sep 01; 9(9):1260-1266. PubMed ID: 37270698
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape.
    Simard MA, Cabrera-Galvez C, Viteri S, Geist F, Reischmann N, Zühlsdorf M, Karachaliou N.
    Neoplasia; 2024 Nov 01; 57():101063. PubMed ID: 39366215
    [Abstract] [Full Text] [Related]

  • 12. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC, INSIGHT Investigators.
    Lancet Respir Med; 2020 Nov 01; 8(11):1132-1143. PubMed ID: 32479794
    [Abstract] [Full Text] [Related]

  • 13. Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non-Small Cell Lung Cancer Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping.
    Yang M, Vioix H, Sachdev R, Stargardter M, Tosh J, Pfeiffer BM, Paik PK.
    Value Health; 2023 Apr 01; 26(4):487-497. PubMed ID: 36503033
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).
    Kang EJ, Yang Y, Lee S, Kim YJ, Lim SM, Ahn MJ, Choi YJ, Lee Y, Kim TM, Kim I, Ahn HK, Jeung HC, Lee SI, Oh SY, Bae WK, Ryu H, Park KH, Lee KH.
    ESMO Open; 2024 Sep 01; 9(9):103668. PubMed ID: 39214049
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Mathieu LN, Larkins E, Akinboro O, Roy P, Amatya AK, Fiero MH, Mishra-Kalyani PS, Helms WS, Myers CE, Skinner AM, Aungst S, Jin R, Zhao H, Xia H, Zirkelbach JF, Bi Y, Li Y, Liu J, Grimstein M, Zhang X, Woods S, Reece K, Abukhdeir AM, Ghosh S, Philip R, Tang S, Goldberg KB, Pazdur R, Beaver JA, Singh H.
    Clin Cancer Res; 2022 Jan 15; 28(2):249-254. PubMed ID: 34344795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.